Metsera (MTSR) Competitors $52.40 -0.10 (-0.19%) As of 02:29 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTSR vs. SMMT, RDY, ASND, VTRS, QGEN, BBIO, MRNA, ROIV, ELAN, and VRNAShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Its Competitors Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen BridgeBio Pharma Moderna Roivant Sciences Elanco Animal Health Verona Pharma PLC American Depositary Share Metsera (NASDAQ:MTSR) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk. Do insiders & institutionals have more ownership in MTSR or SMMT? 4.6% of Summit Therapeutics shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to MTSR or SMMT? In the previous week, Metsera had 22 more articles in the media than Summit Therapeutics. MarketBeat recorded 32 mentions for Metsera and 10 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.71 beat Metsera's score of 0.45 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metsera 12 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate MTSR or SMMT? Metsera presently has a consensus price target of $58.50, suggesting a potential upside of 11.64%. Summit Therapeutics has a consensus price target of $31.29, suggesting a potential upside of 54.35%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Metsera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metsera 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Summit Therapeutics 4 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.53 Is MTSR or SMMT more profitable? Metsera's return on equity of 0.00% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MetseraN/A N/A N/A Summit Therapeutics N/A -208.64%-181.28% Which has preferable earnings & valuation, MTSR or SMMT? Metsera has higher earnings, but lower revenue than Summit Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetseraN/AN/A-$209.13MN/AN/ASummit Therapeutics$700K21,509.75-$221.32M-$1.01-20.07 SummarySummit Therapeutics beats Metsera on 7 of the 12 factors compared between the two stocks. Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.50B$3.07B$5.65B$10.26BDividend YieldN/A2.36%5.68%4.61%P/E RatioN/A20.6875.7026.05Price / SalesN/A397.57514.05168.79Price / CashN/A45.9137.5661.52Price / Book-21.309.6212.876.29Net Income-$209.13M-$52.73M$3.29B$270.94M7 Day Performance45.96%0.59%-0.33%-0.30%1 Month Performance60.79%6.27%3.77%6.20%1 Year PerformanceN/A18.55%68.18%28.32% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$52.40-0.2%$58.50+11.6%N/A$5.50BN/A0.0081Analyst DowngradeSMMTSummit Therapeutics3.1675 of 5 stars$18.94+1.8%$33.79+78.4%-14.6%$13.82B$700K-18.75110Analyst ForecastRDYDr. Reddy's Laboratories2.8902 of 5 stars$14.65-0.5%$16.95+15.7%-9.3%$12.30B$3.81B22.2027,811Positive NewsASNDAscendis Pharma A/S2.8492 of 5 stars$195.58-1.1%$244.36+24.9%+33.4%$12.10B$393.54M-37.901,017VTRSViatris2.0044 of 5 stars$9.96-2.1%$10.40+4.4%-15.2%$11.86B$14.12B-3.4332,000News CoveragePositive NewsQGENQiagen4.3146 of 5 stars$45.30-1.7%$49.69+9.7%+3.2%$10.24B$2.04B26.765,765BBIOBridgeBio Pharma4.541 of 5 stars$51.21-2.6%$63.94+24.9%+103.7%$10.06B$235.81M-12.52400Positive NewsMRNAModerna4.4982 of 5 stars$23.51-7.4%$41.81+77.8%-59.5%$9.88B$3.06B-3.125,800Trending NewsHigh Trading VolumeROIVRoivant Sciences3.2819 of 5 stars$14.08-2.3%$17.67+25.5%+25.7%$9.84B$29.05M-20.11860Insider TradeAnalyst RevisionELANElanco Animal Health2.5918 of 5 stars$18.52-1.4%$17.33-6.4%+35.1%$9.33B$4.48B21.539,000News CoverageAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.0039 of 5 stars$106.43+0.0%$109.00+2.4%+258.7%$8.71B$221.67M-107.5030Positive News Related Companies and Tools Related Companies SMMT Alternatives RDY Alternatives ASND Alternatives VTRS Alternatives QGEN Alternatives BBIO Alternatives MRNA Alternatives ROIV Alternatives ELAN Alternatives VRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTSR Stock Alerts